Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
UnitedHealthcareMedicaid · Prior Auth · Medical Benefit Drug Policy · KY · Genetics, Endocrinology, Pediatrics +1 moreLow impact

Genglycos ™ (Pariglasgene Brecaparvovec-Opnr)

Effective date
Dec 1, 2026
Identified
Nov 7, 2026

Summary

UnitedHealthcare Community Plan of Kentucky published a Medicaid medical benefit drug policy for Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy for glycogen storage disease type Ia, effective 2026-12-01. Coverage is limited to patients 8 years or older who meet diagnostic confirmation, cornstarch therapy, AAV8 antibody-negative, no prior gene therapy, metabolic specialist involvement, no planned inpatient admission solely for administration, FDA-labeled dosing, and an authorization limit of one lifetime treatment valid for no more than 45 days from approval.

Get alerts when payers change rules like this one

We check UnitedHealthcare and other payers every day and email you when a change matches your specialty and state.

Get UnitedHealthcare alertsPolicy Monitoring is free. No card required.

What to do

Action · 3 steps
01By 2026-12-01: Billing team and providers should review the Genglycos criteria for Kentucky Community Plan Medicaid members, confirm which patients meet the age, diagnosis, cornstarch therapy, and AAV8 antibody requirements before scheduling, and build the required chart notes, genetic variant results or liver biopsy enzyme findings, and specialist documentation into the prior authorization request.
02Front desk staff should be told that the one-treatment, 45-day authorization window applies so scheduling aligns with approval dates.
03Claims without the required documentation or authorization will be denied under this policy.

Original notice

Genglycos ™ (Pariglasgene Brecaparvovec-Opnr)
uhcprovider.com · Always check the source before changing claims.
View original ↗

Related changes

See all UnitedHealthcare changes →
Genglycos ™ (Pariglasgene Brecaparvovec-Opnr)MediumEffective Dec 1, 2026 · Medical Benefit Drug PolicyGenglycos ™ (Pariglasgene Brecaparvovec-Opnr)MediumEffective Dec 1, 2026 · Medical Benefit Drug PolicyGenglycos ™ (Pariglasgene Brecaparvovec-Opnr)MediumEffective Dec 1, 2026 · Medical Benefit Drug PolicyGenglycos ™ (Pariglasgene Brecaparvovec-Opnr)LowEffective Dec 1, 2026 · Medical Benefit Drug PolicyBrowse every UnitedHealthcare change in the policy list

Related policy hubs

UnitedHealthcare policiesKY policy changesGeneticsEndocrinologyPediatricsPharmacy

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account